# DECIPHER LABS (NSE: DECIPHER) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/DECIPHER · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹6 Cr, it ranks 4040th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −37.4% in FY26. Promoters held 16.43% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹6 Cr |
| ROE | −37.4% (FY26) |
| ROCE | −44.7% (FY26) |
| Debt to equity | 0.06 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹23 Cr | −₹5 Cr |
| FY24 | ₹36 Cr | −₹2 Cr |
| FY23 | ₹46 Cr | −₹3 Cr |
| FY22 | ₹65 Cr | ₹11 Cr |
| FY21 | ₹56 Cr | ₹1 Cr |
| FY20 | ₹24 Cr | ₹1 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 16.43%
- Foreign institutions: 0.00%
- Non-institutions: 83.57%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Trinity League](https://app.pivotnow.in/stock/TRINITYLEA) | — | ₹8 Cr | — | — |
| [Adline Chem Lab](https://app.pivotnow.in/stock/ADLINE) | — | ₹8 Cr | — | — |
| [Unjha Formula](https://app.pivotnow.in/stock/UNJHAFOR) | — | ₹8 Cr | — | — |
| [Dr Lalchandani](https://app.pivotnow.in/stock/DLCL) | — | ₹7 Cr | — | — |
| [Vivanza Bio](https://app.pivotnow.in/stock/VIVANZA) | — | ₹7 Cr | — | — |
| [Evoq Remedies](https://app.pivotnow.in/stock/EVOQ) | — | ₹6 Cr | — | — |

## Questions and answers

### What is the market cap of DECIPHER LABS?

DECIPHER LABS's market capitalisation is ₹6 Cr (₹6 Cr) at the 22 Oct 2026 close, ranking 4040th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of DECIPHER LABS?

Return on equity was −37.4% in FY26 and return on capital employed was −44.7% in FY26 (consolidated figures).

### Is DECIPHER LABS a debt-free company?

No. DECIPHER LABS's debt-to-equity ratio was 0.06 in FY26, with total debt of ₹0 Cr.

### What is the shareholding pattern of DECIPHER LABS?

As of 30 Jun 2026: promoters 16.43%, foreign institutions 0.00%, non-institutions 83.57%.

### Who are DECIPHER LABS's competitors?

The listed Pharma & Healthcare companies closest to DECIPHER LABS by market cap are Trinity League, Adline Chem Lab, Unjha Formula, Dr Lalchandani, Vivanza Bio and Evoq Remedies.

### Is DECIPHER LABS a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out DECIPHER LABS's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on DECIPHER against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.